Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
MENLO PARK, Calif. & BERLIN - PacBio (NASDAQ:PACB) announced Monday that Lucid Genomics GmbH has joined its Compatible partner program as a solution for tertiary analysis of data generated on PacBio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results